Pyrroloquinoline Quinone (PQQ) for Parkinson's Disease
Also known as: PQQ, BioPQQ, Methoxatin
PQQ's mitochondrial biogenesis addresses Complex I deficiency in Parkinson's by generating new, functional mitochondria.
Mechanism of Action
PQQ-induced PGC-1α activation drives formation of new mitochondria in dopaminergic neurons with Complex I deficits. It also protects existing mitochondria through redox cycling antioxidant activity and enhances BDNF expression for neuroplasticity.
General mechanism: Redox cycling cofactor. PGC-1α/CREB activator for mitochondrial biogenesis. NGF stimulator. Antioxidant (20,000+ redox cycles).
Current Evidence
Preclinical evidence for dopaminergic neuroprotection. PGC-1α activation is an established PD therapeutic target. No PD clinical trials.
Clinical Status: Preclinical. PGC-1α activation in PD is an active research area.
Safety Profile
Very safe. Present in foods (kiwi, parsley). Well-tolerated as supplement. No significant side effects.
Key Research Questions
- Can PQQ rescue mitochondrial function in PD dopaminergic neurons?
- Does PQQ synergize with exercise (which also activates PGC-1α) in PD?